Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

Clinical and Translational Science

Volumn 1, Issue 1, 2008, Pages 36-43

  Goldfine, Allison B ^d   Silver, Robert ^a   Aldhahi, Waleed ^b   Cai, Dongsheng ^c   Tatro, Elizabeth ^d   Lee, Jongsoon ^d   Shoelson, Steven E ^d  

^a Southern New Hampshire Medical Center   (United States)

^b Mubarak Alkabeer University Hospital   (Kuwait)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adiponectin; Glucose; Inflammation; Insulin resistance; Salicylate; Salsalate; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; BIGUANIDE; C PEPTIDE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MISOPROSTOL; PLACEBO; SALSALATE; SULFONYLUREA; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MAXIMUM TOLERATED DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; TINNITUS; CALORIMETRY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GLUCOSE TOLERANCE TEST; HYPERINSULINISM; METABOLISM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; CALORIMETRY; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MALE; NF-KAPPA B; PLACEBOS; SALICYLATES;

EID: 64149121817     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2008.00026.x     Document Type: Article

References (50)

1. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116: 1793-1801.
2. Tataranni PA, Ortega E. A burning question: Does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes. 2005; 54(4): 917-927.
3. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444(7121): 860-867.
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16): 1685-1695.
5. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol. 2006; 6(7): 508-519.
6. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun N-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000; 275(12): 9047-9054.
7. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature. 2002; 420(6913): 333-336.
8. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesityand diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science. 2001; 293(5535): 1673-1677.
9. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKKβ and NF-κB. Nat Med. 2005; 11(2): 183-190.
10. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112(12): 1796-1808.
11. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112(12): 1821-1830.
12. Ebstein W. Zur therapie des diabetes mellitus, insbesondere uber die anwendeng der salicylauren natron bei demselben. Berliner Klinische Wochenschrift. 1876; 13: 337-340.
13. Bartels-Kiel. Ueber die therapeutiche Verwerthung der Salicylsäure und ihres Natronsalzes in der inneren Medicin. Deutsche Medicinische Wochenschrift. 1878; 4: 423-425.
14. Williamson RT. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J. 1901; 1: 760-762.
15. Reid J, Macdougall AI, Andrews MM. On the efficacy of salicylate in treating diabetes mellitus. Br Med J. 1957; 2: 1071-1074.
16. Hecht A, Goldner MG. Reappraisal of the hypoglycemic action of acetylsalicylate. Metabolism. 1959; 8: 418-428.
17. Gilgore SG. The influence of salicylate on hyperglycemia. Diabetes. 1960; 9(5): 392-393.
18. Baron SH. Salicylates as hypoglycemic agents. Diabetes Care. 1982; 5(1): 64-71.
19. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995; 2(8): 637-643.
20. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 1994; 265(5174): 956-959.
21. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol. 1996; 156(10): 3961-3969.
22. Cai D, Frantz JD, Tawa NE, Jr., Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE. IKKβ/ NF-κB activation causes severe muscle wasting in mice. Cell. 2004; 119(2): 285-298.
23. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature. 1998; 396(6706): 77-80.
24. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002; 109(10): 1321-1326.
25. Sweeney JD, Hoernig LA. Hemostatic effects of salsalate in normal subjects and patients with hemophilia A. Thromb Res. 1991; 61(1): 23-27.
26. Edmar D. Effects of salicylates on the gastric mucosa as revealed by roentgen examination and the gastrocamera. Acta Radiol Diagn (Stockh). 1971; 11(1): 57-64.
27. Lanza F, Rack MF, Doucette M, Ekholm B, Goldlust B, Wilson R. An endoscopic comparison of the gastroduodenal injury seen with salsalate and naproxen. J Rheumatol. 1989; 16(12): 1570-1574.
28. Roth S, Bennett R, Caldron P, Hartman R, Mitchell C, Doucette M, Ekholm B, Goldlust B, Lee E, Wilson R. Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): An endoscopic study. Semin Arthritis Rheum. 1990; 19(4 Suppl 2): 11-19.
29. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979; 28(12): 1039-1057.
30. McGuire EA, Helderman JH, Tobin JD, Andres R, Berman M. Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol. 1976; 41(4): 565-573.
31. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237(3): E214-E223.
32. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989; 38(4): 387-395.
33. Ferrannini E. The theoretical bases of indirect calorimetry: A review. Metabolism. 1988; 37(3): 287-301.
34. Aljada A, Ghanim H, Dandona P. Activation of nuclear factor-kappa B (NF-kappa B) in mononuclear cells (MNC). Methods Mol Biol. 2002; 196: 105-110.
35. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation. 2004; 110(12): 1564-1571.
36. Chen M, Robertson RP. Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon. Diabetes. 1978; 27(7): 750-756.
37. Fujimoto WY, Metz SA. Phasic glucose-stimulated insulin secretion by neonatal rat pancreatic islet cells. Enhancement by sodium salicylate. Diabetes. 1984; 33(9): 872-878.
38. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001; 86(7): 3257-3265.
39. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 2001; 86(1): 450-453.
40. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med. 2001; 7(10): 1138-1143.
41. Marletta MA. Nitric oxide synthase: Aspects concerning structure and catalysis. Cell. 1994; 78(6): 927-930.
42. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science. 1992; 258(5090): 1898-1902.
43. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N, Kumada M, Okamoto Y, Nagaretani H, Nishizawa H, Kishida K, Komuro R, Ouchi N, Kihara S, Nagai R, Funahashi T, Matsuzawa Y. Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis. J Biol Chem. 2002; 277(40): 37487-37491.
44. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003; 278(45): 45021-45026.
45. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H, Kishida K, Maeda N, Nagasawa A, Kobayashi H, Hiraoka H, Komai N, Kaibe M, Rakugi H, Ogihara T, Matsuzawa Y. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003; 42(3): 231-234.
46. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001; 86(3): 1306-1312.
47. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004; 89(6): 2728-2735.
48. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 2005; 437(7059): 759-763.
49. The Multicenter Salsalate/Aspirin Comparison Study Group. Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? J Rheumatol. 1989; 16(3): 321-327.
50. April P, Abeles M, Baraf H, Cohen S, Curran N, Doucette M, Ekholm B, Goldlust B, Knee CM, Lee E, Marcus R, Parrino GR, Reese R, Riskin W, Samuels B, Utsinger P, Virshup A, Wenger M, Whelton J, Wilson R. Does the acetyl group of aspirin contribute to the antiinflammatory efficacy of salicylic acid in the treatment of rheumatoid arthritis? Semin Arthritis Rheum. 1990; 19(4 Suppl 2): 20-28.